Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameGenfleet-B
Stock Code02595
Company Full NameGenFleet Therapeutics (Shanghai) Inc.
IndustryNew Energy
Principal Activitiesbiopharmaceutical company based in China, featuring a global vision, international collaborations and operations
Listing Date2025-09-19
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules ChapterChapter 18A
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)1206 Zhangjiang Road (Shanghai) Pilot Free Trade Zone PRC
Business Address (Hong Kong)香港灣仔皇后大道東183號合和中心46樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.genfleet.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar ContactComputershare Hong Kong Investor
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 20.39 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 4,078
Par ValueRMB 0.1 / shares
Offer Period2025-09-11 to 2025-09-16
Global Offering Shares89,240,000 shares
HK Public Offer Shares (Initial)7,760,000 shares (10.0%)
Public Offer Lots (Initial)38,800lots (Pool A19,400lots,Pool B19,400lots)
International Placing Shares (Initial)69,840,000 shares (90.0%)
Offer Ratio~25.84%
Total Shares Post-IPO345,340,630 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)中信证券(香港)有限公司 CE AAK249
Cornerstone Share42.9%
Clawback TiersMechanism B: no clawback
Reallocation OptionNo
Total Global Offering SizeHK$ 1,819,603,600

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 4,078
2 lots 400 HK$ 8,156
3 lots 600 HK$ 12,234
4 lots 800 HK$ 16,312
5 lots 1,000 HK$ 20,390
6 lots 1,200 HK$ 24,468
7 lots 1,400 HK$ 28,546
8 lots 1,600 HK$ 32,624
9 lots 1,800 HK$ 36,702
10 lots 2,000 HK$ 40,780
15 lots 3,000 HK$ 61,170
20 lots 4,000 HK$ 81,560
25 lots 5,000 HK$ 101,950
30 lots 6,000 HK$ 122,340
35 lots 7,000 HK$ 142,730
40 lots 8,000 HK$ 163,120
45 lots 9,000 HK$ 183,510
50 lots 10,000 HK$ 203,900
100 lots 20,000 HK$ 407,800
150 lots 30,000 HK$ 611,700
200 lots 40,000 HK$ 815,600
250 lots 50,000 HK$ 1,019,500
300 lots 60,000 HK$ 1,223,400
350 lots 70,000 HK$ 1,427,300
400 lots 80,000 HK$ 1,631,200
450 lots 90,000 HK$ 1,835,100
500 lots 100,000 HK$ 2,039,000
750 lots 150,000 HK$ 3,058,500
1,000 lots 200,000 HK$ 4,078,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,250 lots 250,000 HK$ 5,097,500
1,500 lots 300,000 HK$ 6,117,000
1,750 lots 350,000 HK$ 7,136,500
2,000 lots 400,000 HK$ 8,156,000
2,250 lots 450,000 HK$ 9,175,500
2,500 lots 500,000 HK$ 10,195,000
3,000 lots 600,000 HK$ 12,234,000
3,500 lots 700,000 HK$ 14,273,000
4,000 lots 800,000 HK$ 16,312,000
4,500 lots 900,000 HK$ 18,351,000
5,000 lots 1,000,000 HK$ 20,390,000
7,500 lots 1,500,000 HK$ 30,585,000
10,000 lots 2,000,000 HK$ 40,780,000
12,500 lots 2,500,000 HK$ 50,975,000
15,000 lots 3,000,000 HK$ 61,170,000
19,400 lots 3,880,000 HK$ 79,113,200

Stock Connect Inclusion Analysis

HK Market Cap HK$ 10.41B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 7,041,495,445
H-Share Market Cap (at Offer Price)HK$ 6,619,471,177
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot applicable (loss-making)
Profit/Loss StatusNet loss RMB 677.6 million
Period-End Cash BalanceRMB 362.12 million
Listing Expenses~HK$ 138,800,000
Listing Expenses / Funds Raised~8.8%
Total Pre-IPO Investmentapproximately RMB 1,421 million
First Day CloseHK$ 42.1
First Day OpenHK$ 44.0
First Day Change106.47%
First Day Volume34913500.0
First Day Turnover1552900000.0
Use of Proceeds
1、約1,024.9百萬港元(或約71.0%)將用作核心產品GFH925及GFH375的進一步開發資金; 2、約274.3百萬港元(或約19.0%)將用作為其他候選產品的開發提供資金; 3、約144.4百萬港元(或約10%)將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
中信证券(香港)有限公司 CE AAK249(sole)
Sponsor cum Overall Coordinator (1)
中信里昂证券有限公司 CE AAB893(sole)
Overall Coordinators (4)
中信里昂证券有限公司 CE AAB893 交银国际证券有限公司 CE APJ121 Fosun International Securities Limited CE AAF432 农银国际融资有限公司 CE AWL249
Joint Global Coordinators (5)
中信里昂证券有限公司 CE AAB893 交银国际证券有限公司 CE APJ121 Fosun International Securities Limited CE AAF432 农银国际融资有限公司 CE AWL249 建银国际金融有限公司 CE AJO225
Joint Bookrunners (7)
中信里昂证券有限公司 CE AAB893 交银国际证券有限公司 CE APJ121 Fosun International Securities Limited CE AAF432 农银国际融资有限公司 CE AWL249 China Renaissance Securities (Hong Kong) Limited CE AZX839 建银国际金融有限公司 CE AJO225 广发证券(香港)经纪有限公司 CE AOB364
Joint Lead Managers (7)
中信里昂证券有限公司 CE AAB893 交银国际证券有限公司 CE APJ121 Fosun International Securities Limited CE AAF432 农银国际证券有限公司 CE ACX411 China Renaissance Securities (Hong Kong) Limited CE AZX839 建银国际金融有限公司 CE AJO225 广发证券(香港)经纪有限公司 CE AOB364
Capital Market Intermediaries (8)
中信里昂证券有限公司 CE AAB893 交银国际证券有限公司 CE APJ121 Fosun International Securities Limited CE AAF432 农银国际融资有限公司 CE AWL249 农银国际证券有限公司 CE ACX411 China Renaissance Securities (Hong Kong) Limited CE AZX839 建银国际金融有限公司 CE AJO225 广发证券(香港)经纪有限公司 CE AOB364
Stabilizing Manager (1)
中信证券(香港)有限公司 CE AAK249

Service Providers

RoleInstitution
Legal Advisor to Company Davis Polk & Wardwell
嘉源律师事务所
君合律师事务所
Jun He Law Offices P.C.
Legal Advisor to Sponsors/Underwriters 苏利文•克伦威尔律师事务所(香港)有限法律责任合伙
竞天公诚律师事务所
Auditor and Reporting Accountant 安永会计师事务所
Industry Advisor 弗若斯特沙利文(北京)咨询有限公司上海分公司
Compliance Advisor 国泰君安融资有限公司 CE AGS488
Receiving Banks 中信银行(国际)有限公司

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Lake Bleu Innovation Healthcare Master Fund Limited 16,838,062 HKD — 0.93% — 6 months 2026-03-19
2 Lake Bleu Prime Healthcare Master Fund Limited 29,859,116 HKD — 1.64% — 6 months 2026-03-19
3 LBC HK Opportunity Fund Limited 31,261,948 HKD — 1.72% — 6 months 2026-03-19
4 OrbiMed Funds 97,447,888 HKD — 5.35% — 6 months 2026-03-19
5 RTW Funds 116,940,728 HKD — 6.43% — 6 months 2026-03-19
6 TruMed 97,447,888 HKD — 5.36% — 6 months 2026-03-19
7 UBS Asset Management (Singapore) Ltd. 77,959,126 HKD — 4.28% — 6 months 2026-03-19
8 Vivo Funds 77,959,126 HKD — 4.28% — 6 months 2026-03-19
9 富国基金管理有限公司 62,368,932 HKD — 3.43% — 6 months 2026-03-19
10 富国资产管理(香港)有限公司 15,590,194 HKD — 0.86% — 6 months 2026-03-19
11 汇添富基金管理股份有限公司 15,590,194 HKD — 0.86% — 6 months 2026-03-19
12 汇添富资产管理(香港)有限公司 62,368,932 HKD — 3.43% — 6 months 2026-03-19
13 中信证券国际资本管理有限公司 77,959,126 HKD — 4.28% — 6 months 2026-03-19

Directors & Management

PositionChinese nameEnglish Name
Chairman呂強—
Company Secretary張巍—
No director data available.

Major Shareholders

Major Shareholders & HoldingsDr. Lü holds approximately 19.57% equity interest (after the Global Offering) through Shanghai Kunjin and Jianfa Hong Kong; Dr. Lan holds approximately 15.56% equity interest through Jianfa Hong Kong; Ourea Biotech holds approximately 6.49% equity interest; Changxing holds approximately 4.37% equity interest; Hongyong Bingde holds approximately 3.81% unlisted shares; Sinopharm Zhongsheng holds approximately 1.37% equity interest and 1.37% unlisted shares; CSPC Group Enbipu holds approximately 1.28% unlisted shares; Pu'en Guoxin holds approximately 1.15% unlisted shares; Huajin Lingjian holds approximately 0.68% equity interest and 0.68% unlisted shares; Bank of Communications Sci-Tech Innovation holds approximately 0.55% unlisted shares.
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.

Market Sentiment

The IPO of 劲方医药-B recorded an extreme oversubscription ratio of 2,662.79x, indicating frenzy-level retail demand. A hit rate of just 12.76% reflects severe allocation scarcity, and the offer price was fixed at HK$20.39 with no range to anchor expectations. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

Without detailed tier distribution data, specific inefficiencies like 甲尾 vs 乙头 cannot be assessed. Reallocation from the international tranche was triggered, suggesting strong retail demand overwhelmed the 8.7% initial public offer portion, but the impact on allocation tiers is unclear. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice. Data may contain errors or omissions; verify against official filings.)

Demographics

Official demographic data for subscribed investors is unavailable. For biotech listings with such extreme oversubscription, a high proportion of mainland retail participation is typical, but no breakdown is provided. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Genfleet-B (02595) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect